Drugs.com - Clinical Trials

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa.--(BUSINESS WIRE) May 18, 2025 -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International...

May 26, 2025 - 06:50
 0
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE) May 18, 2025 -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International...
Read More

Tags:

Previous Article

Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity...

Next Article

FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatm...

Related Posts

AI Screening for Opioid Use Disorder Associated with Fewer Hospital Readmissions

AI Screening for Opioid Use Disorder Associated with Fe...

May 12, 2025  0

In New SELECT Trial Analysis, Early Reduction in Cardiovascular Events Was Observed with Wegovy®, Before Clinically Meaningful Changes in Body Weight

In New SELECT Trial Analysis, Early Reduction in Cardio...

May 14, 2025  0

Boehringer Ingelheim Starts Phase II Study of BI 1584862, Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim Starts Phase II Study of BI 158486...

May 12, 2025  0